OptiBiotix Health

OptiBiotix is a life sciences company in the field of human microbiome modulation. OptiBiotix is conducting research into prebiotic and probiotic products that modulate the human microbiome to produce a health benefit. OptiBiotix has a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest, and appetite suppression.
History
OptiBiotix was established by microbiologist Stephen O’Hara in March 2012 following the establishment of the Human Microbiome Project. OptiBiotix was formed to develop compounds which modify the human microbiome, the collective genome of the microbes in the body, to prevent and manage human disease.
Research
On 1 February 2017 OptiBiotix presented posters at the ProBiota 2017 conference that showed OptiBiotix’s probiotic, LP-LDL® reduces blood pressure and cholesterol, key determinates of cardiovascular risk. In addition, by combining LP-LDL® with a microbiome modulator, OptiBiotix were able to selectively enhance LP-LDL® growth and biological activity. Combining the probiotic with a microbiome modulator achieved three times the cholesterol-reduction than using the probiotic alone. The research was carried out in collaboration with Professor Glenn Gibson, Professor of Food Microbiology, Head of Food Microbial Sciences at Reading University, and Professor Bob Rastall, Professor of Food Biotechnology and Head of Food and Nutritional Sciences at Reading University.

Main Menu

See Also

Main Menu